The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Lol, it does make me laugh when I read about TW and his ethical considerations. Frankly speaking Bakky, the market response to our announcement has been a bit underwhelming. No doubt we will re rate accordingly when everyone starts to appreciate what a bargain YGEN is in a few months time. Personally speaking, I sold the trading part of my YGEN holding today because there are better opportunities elsewhere for the next month or two. I fully intend to reinvest back into YGEN wi5 the part I sold today and all my profits I make wi5 my other investment.
Lol. Frankly speaking Bakky, the market response to our announcement has been a bit underwhelming. No doubt we will re rate accordingly when everyone starts to appreciate what a bargain YGEN is but personally speaking, both my wife and I sold a large number of shares today because there are better opportunitie
Thanks very much for sharing that Twix. Very useful information about being cash flow positive and the message conveyed to the II’s in the recent roadshow.
I was pleasantly surprised that it actually did get published this morning, it appears that TW was correct, albeit I still find that a little disturbing that he knew before we did. Anyway, solid results that should hopefully get us up to 15p+ as a new SP floor, until the clarity around our future cash position becomes clearer, presumably in the next month or two based on cash in the bank at present and then hopefully we can take the next SP step up to circa 20p. I don’t see a big drama around that or a placing as there are better options available now they are debt free but the market will want clarity I would expect.
I will be a little disappointed if the trading statement does appear on Monday to be honest. TW should not be privy to that information before we are, and if he is, then he should definitely not be shouting about it in public domain, in my opinion anyway. Just feels unethical to me and I doubt very much that a professional such as Lyn Rees would want it to appear that way. Personally, I don’t expect the TS before mid April, which is two weeks after financial year end close but timing is really irrelevant in the grand scheme of things as long as revenue is upwards of £9M.
I’m confident that it will be a detailed trading update Flipper, as it was last year. It’s only been in the previous years of stagnation around the litigation that they have been somewhat lacking. Worst case scenario, we would have to wait until July, which I really can’t see but if it happened then it would just be an extended period to carry on buying at a heavily undervalued price on my opinion. Time will tell but I’m very relaxed these days.
Agreed Bakky. All we need now in the trading update (due by end of April) is a minimum of £4.5m in H2 to meet the 2019E figures in the Hardman report and we’ll have achieved £8.5m for the year. Anything more in this ‘potentially best ever performance period’ according to Rees, and things will start to get even more exciting on the SP front. Surely the floor has to move to at least 15p+ very soon.
The Proactive Investors article is a good PR exercise, with a couple of new pieces of information that I found particularly interesting and had not heard before: ‘Men’s fertility, spotting the possibility for premature births or a mother at risk of a heart attack during pregnancy are all tests under development.’ ‘Now, though, 60% of its opportunity pipeline is the US.’
I hear you Goggins but I think you are maybe winding yourself up unessecarrily, if you are in this for the long term.
We achieved £3.9M revenue in H1 and according to Lyn in the restructuring RNS ‘Trading in the second half of the current financial year is anticipated to be the strongest period to date’. Clearly that means it is going to exceed what we did in H1 and the 2019E figure in the latest Hardman report is 8.68M, which I personally feel is very conservative when you consider markets such as India have been ramping up significantly in H2.
It has been one hell of a rollercoaster ride over the last few years and I am sure all LTH would agree that we think the SP is much lower than it should be based on the fact we are in such a fantastic position now. However, we need to be realistic and understand that the market wants projected 2019E figures from the Hardman report to be substantiated and we will see what they look like as part of the trading update, which is likely to be issued before the end of April. If they are as good as we all hope and exceed the forecast then I would expect the SP to bounce and I doubt we will see sub 15p again.
Extra capital may also be required at some point for 2019/20, which creates some level of uncertainty in the market and therefore the SP until that is clarified in due course, although clearly it’s not an issue based on our balance sheet now and other options that are available without creating further dilution. For me, that is a non issue but Mr Market obviously needs clarity because that’s how it works.
In my opinion, it is truly a great time to be involved in this share and I am 100% confident that the share price will re rate heavily over the next 2-3 years. Just the fact that Lyn said he expected YGEN to go into an additional 30 countries, on top of the 20 we are already in during his recent interview, gets me extremely excited.
Thanks John. I’ve been in and out a few times over the last four years but frankly speaking, at this price it’s a no brainier for me at the moment, so I’m all in. Best of luck to us all.
Actually there were 4 of those John but only 3 showed up for some reason. I have inside knowledge on that particular set of trades ;)
The SP feels very light considering where we are commercially now but it is what it is until we get H2 figures in the trading update in April/May and the hard facts will set the SP at the correct level. Until then, it’s a significantly risk reduced buying opportunity as far as I’m concerned.
They have also amended their stance around potential additional capital requirements:
‘Financing flexibility: Clearance of the TMO debt has strengthened the balance sheet and provided management with the capacity to establish more normal banking facilities and/or seek asset finance. While this may not obviate the need for more capital, it does provide greater flexibility regarding its timing.’
I agree Truro and Hardman have released this morning, a revised research document this titled ‘Yourgene EBITDA Positive by Fiscal 2020’, which is very positive.
https://www.hardmanandco.com/research/corporate-research/ebitda-positive-in-fiscal-2020/?dm_i=49CL,I2TK,4PJMW6,230H9,1
In addition to the Taiwan Expo at the end of this month where they have a stand and will also be presenting on stage, they now have a number of additional events that they will be present at in 2019, so all good PR:
MEDLAB Exhibition and Congress, 4 - 7 February 2019, Dubai
Forum Labo & Biotech Exhibition, 26 - 28 March 2019, Paris (alongside their partner Adgenix)
Medlab Asia Pacific, 27 - 29 March 2019, Singapore
Asia Pacific Initiative on Reproduction ASPIRE 2019, 2 - 5 May 2019, Hong Kong
European Society of Human Genetics ESHG 2019, 15 - 18 June 2019, Gothenberg, Sweden
I’m sure there will be more news but how and when is an unknown at the moment but I’m feeling optimistic about key announcements through November and December, with the Taiwan expo, interims and 3 year business plan all in the pipeline.
Having a dig through the Annual Report I found that Peter C invoiced Premaitha for circa £256k for ‘consultancy services’, so whilst this does not necessary correlate to his salary, it does give as an indication of the potential annual cost saving made with his departure.
I would be keen to better understand the specific remits that Nick and Hayden both have to be honest because I can only limited conclusions using online information available.
Kind words were said about him and quite rightly so but I totally agree that this was unnecessary cost in the management structure that was inevitably going to get trimmed once Lyn had got his man Hayden in situ. Nick has a very strong organisational background and clearly a lot of valuable experience, having gone through his Linkedin profile, but I do still question whether his days could also be numbered. Time will tell.
I didn’t realise he had spent time with Illumina but that very interesting. He’s definetely the right calibre of person to be representing them at this sort of event and hopefully helping bag some new business.